• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
The Hypervirulent Strain of Clostridium Difficile: NAP1/B1/027 - A Brief Overview.艰难梭菌高毒力菌株：NAP1/B1/027——简要概述
Cureus. 2019 Jan 29;11(1):e3977. doi: 10.7759/cureus.3977.
2
Epidemic Clostridium difficile strains demonstrate increased competitive fitness compared to nonepidemic isolates.流行的艰难梭菌菌株与非流行分离株相比，表现出更高的竞争适应力。
Infect Immun. 2014 Jul;82(7):2815-25. doi: 10.1128/IAI.01524-14. Epub 2014 Apr 14.
3
A portrait of the geographic dissemination of the Clostridium difficile North American pulsed-field type 1 strain and the epidemiology of C. difficile-associated disease in Québec.艰难梭菌北美脉冲场型1菌株的地理传播情况以及魁北克艰难梭菌相关疾病的流行病学情况概述。
Clin Infect Dis. 2007 Jan 15;44(2):238-44. doi: 10.1086/510391. Epub 2006 Dec 6.
4
Comparison of strain typing results for Clostridium difficile isolates from North America.比较北美分离的艰难梭菌的菌株分型结果。
J Clin Microbiol. 2011 May;49(5):1831-7. doi: 10.1128/JCM.02446-10. Epub 2011 Mar 9.
5
Rapid spread of Clostridium difficile NAP1/027/ST1 in Chile confirms the emergence of the epidemic strain in Latin America.艰难梭菌NAP1/027/ST1在智利的迅速传播证实了该流行菌株在拉丁美洲的出现。
Epidemiol Infect. 2015 Oct;143(14):3069-73. doi: 10.1017/S0950268815000023. Epub 2015 Feb 17.
6
The evolving epidemiology of infection in Canadian hospitals during a postepidemic period (2009-2015).加拿大医院在后疫情时期（2009-2015 年）中感染的流行病学演变。
CMAJ. 2018 Jun 25;190(25):E758-E765. doi: 10.1503/cmaj.180013.
7
Impact of the NAP-1 strain on disease severity, mortality, and recurrence of healthcare-associated Clostridium difficile infection.NAP-1菌株对医疗保健相关艰难梭菌感染的疾病严重程度、死亡率和复发率的影响。
Anaerobe. 2017 Dec;48:1-6. doi: 10.1016/j.anaerobe.2017.06.009. Epub 2017 Jun 21.
8
Update on Clostridium difficile infection.艰难梭菌感染的最新进展。
Curr Opin Gastroenterol. 2011 Jan;27(1):38-47. doi: 10.1097/MOG.0b013e3283411634.
9
The first case of antibiotic-associated colitis by Clostridium difficile PCR ribotype 027 in Korea.韩国首例由艰难梭菌PCR核糖型027引起的抗生素相关性结肠炎病例。
J Korean Med Sci. 2009 Jun;24(3):520-4. doi: 10.3346/jkms.2009.24.3.520. Epub 2009 Jun 16.
10
Fidaxomicin: a macrocyclic antibiotic for the treatment of Clostridium difficile infection.非达霉素：一种用于治疗艰难梭菌感染的大环内酯类抗生素。
Pharmacotherapy. 2011 Sep;31(9):877-86. doi: 10.1592/phco.31.9.877.

引用本文的文献

1
Dominance of toxigenic strains and the appearance of the emerging PCR ribotype 955 in hospitals in Silesia, Poland.波兰西里西亚医院中产毒菌株的优势地位及新出现的PCR核糖体分型955的出现。
Front Microbiol. 2025 Aug 11;16:1644051. doi: 10.3389/fmicb.2025.1644051. eCollection 2025.
2
Extraintestinal Manifestations of Infections: An Overview.感染的肠外表现：概述
Antibiotics (Basel). 2025 Jul 2;14(7):670. doi: 10.3390/antibiotics14070670.
3
Evaluating Vancomycin Monotherapy and Dual Therapy with Nifuroxazide for Medium-Severe Clostridioides Difficile Infection.评估万古霉素单药治疗及与硝呋太尔联合治疗中重度艰难梭菌感染的效果
Antibiotics (Basel). 2025 Apr 14;14(4):400. doi: 10.3390/antibiotics14040400.
4
Synthesis of PSI Oligosaccharide for the Development of Total Synthetic Vaccine against .用于开发抗……全合成疫苗的PSI寡糖的合成
J Org Chem. 2025 Apr 25;90(16):5586-5613. doi: 10.1021/acs.joc.5c00290. Epub 2025 Apr 11.
5
Citrulline Inhibits Clostridioides difficile Infection With Anti-inflammatory Effects.瓜氨酸通过抗炎作用抑制艰难梭菌感染。
Cell Mol Gastroenterol Hepatol. 2025;19(6):101474. doi: 10.1016/j.jcmgh.2025.101474. Epub 2025 Feb 7.
6
A cell-free gene expression system for prototyping and gene expression analysis.一种用于原型制作和基因表达分析的无细胞基因表达系统。
Appl Environ Microbiol. 2025 Jan 31;91(1):e0156624. doi: 10.1128/aem.01566-24. Epub 2024 Dec 31.
7
Chemical optimization and derivatization of micrococcin p2 to target multiple bacterial infections: new antibiotics from thiopeptides.化学优化和微球菌素 p2 的衍生化以靶向多种细菌感染：来自硫肽的新型抗生素。
World J Microbiol Biotechnol. 2024 Aug 20;40(10):307. doi: 10.1007/s11274-024-04109-5.
8
Clinical Characteristics and Risk Factors for Infection in the Hematopoietic Cell Transplantation Population.造血细胞移植人群感染的临床特征及危险因素
Res Sq. 2024 Jul 10:rs.3.rs-4531064. doi: 10.21203/rs.3.rs-4531064/v1.
9
Development of multi-epitope mRNA vaccine against using reverse vaccinology and immunoinformatics approaches.使用反向疫苗学和免疫信息学方法开发针对……的多表位mRNA疫苗。 （原文中“against”后缺少具体对象）
Synth Syst Biotechnol. 2024 May 18;9(4):667-683. doi: 10.1016/j.synbio.2024.05.008. eCollection 2024 Dec.
10
": The Epidemiology of Toxigenic Strains in the Antibiotic Era-Insights from a Prospective Study at a Regional Infectious Diseases Hospital in Eastern Europe.：抗生素时代产毒菌株的流行病学——来自东欧一家地区传染病医院前瞻性研究的见解。
Antibiotics (Basel). 2024 May 17;13(5):461. doi: 10.3390/antibiotics13050461.

本文引用的文献

1
Current updates in management of Clostridium difficile infection in cancer patients.癌症患者艰难梭菌感染的治疗新进展。
Curr Med Res Opin. 2019 Mar;35(3):473-478. doi: 10.1080/03007995.2018.1487389. Epub 2018 Jul 5.
2
Prevalence of Clostridium difficile infection in hospitalized patients with diarrhoea: Results of a Polish multicenter, prospective, biannual point-prevalence study.住院腹泻患者艰难梭菌感染的患病率：一项波兰多中心、前瞻性、半年一次的现患率研究结果
Adv Med Sci. 2018 Sep;63(2):290-295. doi: 10.1016/j.advms.2018.03.003. Epub 2018 Apr 16.
3
Genomic and phenotypic diversity of Clostridium difficile during long-term sequential recurrences of infection.艰难梭菌在长期序贯感染复发过程中的基因组和表型多样性。
Int J Med Microbiol. 2018 Apr;308(3):364-377. doi: 10.1016/j.ijmm.2018.02.002. Epub 2018 Feb 21.
4
Circulation of Highly Drug-Resistant Clostridium difficile Ribotypes 027 and 001 in Two Tertiary-Care Hospitals in Mexico.墨西哥两家三级护理医院中高耐药性艰难梭菌核糖体分型027和001的传播情况
Microb Drug Resist. 2018 May;24(4):386-392. doi: 10.1089/mdr.2017.0323. Epub 2018 Feb 27.
5
Clinical Practice Guidelines for Clostridium difficile Infection in Adults and Children: 2017 Update by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA).临床实践指南：成人和儿童艰难梭菌感染：美国传染病学会（IDSA）和美国医疗保健流行病学学会（SHEA） 2017 年更新。
Clin Infect Dis. 2018 Mar 19;66(7):e1-e48. doi: 10.1093/cid/cix1085.
6
PCR ribotyping and antimicrobial susceptibility testing of isolates of Clostridium difficile cultured from toxin-positive diarrheal stools of patients receiving medical care in Canadian hospitals: the Canadian Clostridium difficile Surveillance Study (CAN-DIFF) 2013-2015.从加拿大医院接受医疗护理的患者毒素阳性腹泻粪便中培养的艰难梭菌分离株的PCR核糖分型和药敏试验：2013 - 2015年加拿大艰难梭菌监测研究（CAN - DIFF）
Diagn Microbiol Infect Dis. 2018 Jun;91(2):105-111. doi: 10.1016/j.diagmicrobio.2018.01.017. Epub 2018 Jan 31.
7
Prevalence of the Clostridium difficile BI/NAP1/027 strain across the United States Veterans Health Administration.艰难梭菌 BI/NAP1/027 在美国退伍军人健康管理局的流行情况。
Clin Microbiol Infect. 2018 Aug;24(8):877-881. doi: 10.1016/j.cmi.2017.11.011. Epub 2017 Nov 22.
8
The ClosER study: results from a three-year pan-European longitudinal surveillance of antibiotic resistance among prevalent Clostridium difficile ribotypes, 2011-2014.ClosER 研究：2011-2014 年期间普遍流行的艰难梭菌核糖体分型的抗生素耐药性的三年泛欧纵向监测结果。
Clin Microbiol Infect. 2018 Jul;24(7):724-731. doi: 10.1016/j.cmi.2017.10.008. Epub 2017 Oct 21.
9
Surotomycin versus vancomycin in adults with Clostridium difficile infection: primary clinical outcomes from the second pivotal, randomized, double-blind, Phase 3 trial.索罗米星与万古霉素治疗成人艰难梭菌感染：第二项关键性、随机、双盲、3 期临床试验的主要临床结局。
J Antimicrob Chemother. 2017 Dec 1;72(12):3462-3470. doi: 10.1093/jac/dkx299.
10
Impact of the NAP-1 strain on disease severity, mortality, and recurrence of healthcare-associated Clostridium difficile infection.NAP-1菌株对医疗保健相关艰难梭菌感染的疾病严重程度、死亡率和复发率的影响。
Anaerobe. 2017 Dec;48:1-6. doi: 10.1016/j.anaerobe.2017.06.009. Epub 2017 Jun 21.

艰难梭菌高毒力菌株：NAP1/B1/027——简要概述

The Hypervirulent Strain of Clostridium Difficile: NAP1/B1/027 - A Brief Overview.

作者信息

Fatima Rawish, Aziz Muhammad

机构信息

Internal Medicine, Dow University of Health Sciences, Karachi, PAK.

Internal Medicine, University of Kansas Medical Center, Kansas City, USA.

出版信息

Cureus. 2019 Jan 29;11(1):e3977. doi: 10.7759/cureus.3977.

DOI:10.7759/cureus.3977
PMID:30967977
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6440555/
Abstract

Clostridium difficile is a gram-positive bacterium notorious for causing epidemic diarrhea globally with a significant health burden. The pathogen is clinically challenging with increasing antibiotic resistance and recurrence rate. We provide here an in-depth review of one particular strain/ribotype 027, commonly known as NAP1/B1/027 or North American pulsed-field gel electrophoresis type 1, restriction endonuclease analysis type B1, polymerase chain reaction ribotype 027, which has shown a much higher recurrence rate than other strains.

摘要

艰难梭菌是一种革兰氏阳性细菌，因其在全球范围内引发流行性腹泻并造成重大健康负担而臭名昭著。随着抗生素耐药性和复发率的增加，这种病原体在临床上具有挑战性。我们在此对一种特定菌株/核糖型027进行深入综述，该菌株通常被称为NAP1/B1/027或北美脉冲场凝胶电泳1型、限制性内切酶分析B1型、聚合酶链反应核糖型027，其复发率比其他菌株高得多。